IRVINE, Calif., June 23, 2026
Allergan Aesthetics, an AbbVie company, announced that Health Canada has approved Boey® (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines (frown lines) in adult patients. The approval marks a major milestone in aesthetic medicine, making Canada the first country to authorize a botulinum neurotoxin serotype E for cosmetic use. Boey® is the first and only rapid-onset, short-duration neurotoxin approved for this indication, offering patients visible results in as little as eight hours after treatment while effects typically wear off within two to three weeks. The innovative profile provides physicians and patients with a flexible treatment option, particularly for individuals interested in trying facial injectables without committing to the longer-lasting effects of traditional neurotoxins.
Phase 3 Clinical Trials Demonstrated Rapid Efficacy and Favorable Safety
The approval is supported by data from two randomized, multicenter, double-blind, placebo-controlled Phase 3 clinical trials (M21-500 and M21-508) involving 947 adults with moderate to severe glabellar lines. Patients received either Boey® 700 units or placebo, with the primary endpoint evaluating improvement in wrinkle severity using the Facial Wrinkle Scale (FWS) on Day 7. The studies demonstrated statistically significant efficacy, with composite responder rates of 60.0% and 65.7%, respectively, compared with placebo. Clinical results also showed that treatment effects began as early as eight hours after injection, while wrinkle severity generally returned to baseline within 14 to 21 days, supporting the product’s differentiated short-duration profile. The most commonly reported treatment-related adverse events included headache, injection-site pain, and injection-site erythema, with most events being mild and consistent with established neurotoxin safety profiles.
Boey Expands Options for Patients Seeking Facial Injectables
According to Allergan Aesthetics, consumer research found that 80% of individuals are interested in learning about new aesthetic treatments, while 79% would prefer the opportunity to temporarily preview treatment results before committing to longer-lasting cosmetic procedures. Boey® was specifically developed to address this unmet need by providing a rapid-onset neurotoxin with a significantly shorter duration of effect than conventional botulinum toxin products. Developed by the makers of BOTOX Cosmetic®, the product offers healthcare professionals another tool to personalize treatment plans based on individual patient preferences and aesthetic goals. BOTOX Cosmetic® remains the only neurotoxin clinically evaluated for use following treatment with Boey®, supporting treatment continuity for patients who later choose longer-lasting aesthetic procedures.
Advertisement
Allergan Aesthetics Strengthens Leadership in Injectable Innovation
The approval reinforces Allergan Aesthetics’ commitment to advancing innovation in the global medical aesthetics market through differentiated injectable technologies. The company plans to begin training healthcare professionals across Canada while preparing for the commercial launch of Boey® in the coming months. Regulatory submissions are also under review in multiple international markets as Allergan Aesthetics seeks to expand global access to the product. As the first approved botulinum neurotoxin serotype E for aesthetic use, Boey® represents an important scientific advancement that broadens treatment choices for both clinicians and patients. With its rapid onset, short treatment duration, and clinically demonstrated efficacy, the product has the potential to reshape the facial injectable market by offering a flexible, patient-friendly option that complements the company’s established BOTOX Cosmetic® portfolio while driving the next generation of aesthetic innovation.
Source: Allergan Aesthetics press release
